Cargando…

Use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy

BACKGROUND: Evaluate the safety and effectiveness of using an endoscopic tissue morcellator (ETM) to remove the retroperitoneal fat during retroperitoneoscopic radical nephrectomy (RRN). METHODS: The use of ETM in the removal of retroperitoneal fat was retrospectively analyzed in patients who underw...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guang, Xu, Yong, Wan, Shaw P., Qu, Genyi, Nie, Haibo, Duan, Guangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164161/
https://www.ncbi.nlm.nih.gov/pubmed/32303216
http://dx.doi.org/10.1186/s12893-020-00740-9
_version_ 1783523237325438976
author Yang, Guang
Xu, Yong
Wan, Shaw P.
Qu, Genyi
Nie, Haibo
Duan, Guangjun
author_facet Yang, Guang
Xu, Yong
Wan, Shaw P.
Qu, Genyi
Nie, Haibo
Duan, Guangjun
author_sort Yang, Guang
collection PubMed
description BACKGROUND: Evaluate the safety and effectiveness of using an endoscopic tissue morcellator (ETM) to remove the retroperitoneal fat during retroperitoneoscopic radical nephrectomy (RRN). METHODS: The use of ETM in the removal of retroperitoneal fat was retrospectively analyzed in patients who underwent RRN for localized renal cancer in our hospital from January 2010 to January 2018. We accrued the appropriate patients and divided them into two groups. The first group included patients of RRN where ETM was used to remove the retroperitoneal fat, while the second group was comprised of patients of RRN where ETM was not performed, which served as the control group. Each group was further divided into two subgroups, including obese patients (BMI ≥ 28) and patients suffering from high-volume renal cancer (Stage T2a). The differences between the two groups as well as their subgroups were analyzed and statistically compared. RESULTS: All 222 nephrectomies were completed under retroperitoneoscopy, ETM was used in 105 of these 222 patients. Among them, 31 cases were of obese patients, and 26 cases were of high-volume renal cancer patients. The other 117 patients had undergone RRN without the use of ETM. Among them, 36 cases were of obese patients, and 28 cases were of high-volume renal cancer patients. The differences in age, BMI, tumor position, and tumor size between the two groups were not statistically significant, P > 0.05. Both the surgical time and the blood loss for the ETM group were significantly lower than the control group, p < 0.05. In the subgroup analysis, the obese patients and patients with high tumor volume also showed a significantly lower surgical time and less blood loss, p < 0.05. The postoperative hospitalization time, the total survival rate, and the disease-free survival rate were not statistically significant, p > 0.05. CONCLUSIONS: The use of ETM in removing the retroperitoneal fat during the RRN can potentially reduce the surgical time and lessen the blood loss. This technique is especially advantageous for obese and large-volume tumor patients.
format Online
Article
Text
id pubmed-7164161
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71641612020-04-22 Use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy Yang, Guang Xu, Yong Wan, Shaw P. Qu, Genyi Nie, Haibo Duan, Guangjun BMC Surg Research Article BACKGROUND: Evaluate the safety and effectiveness of using an endoscopic tissue morcellator (ETM) to remove the retroperitoneal fat during retroperitoneoscopic radical nephrectomy (RRN). METHODS: The use of ETM in the removal of retroperitoneal fat was retrospectively analyzed in patients who underwent RRN for localized renal cancer in our hospital from January 2010 to January 2018. We accrued the appropriate patients and divided them into two groups. The first group included patients of RRN where ETM was used to remove the retroperitoneal fat, while the second group was comprised of patients of RRN where ETM was not performed, which served as the control group. Each group was further divided into two subgroups, including obese patients (BMI ≥ 28) and patients suffering from high-volume renal cancer (Stage T2a). The differences between the two groups as well as their subgroups were analyzed and statistically compared. RESULTS: All 222 nephrectomies were completed under retroperitoneoscopy, ETM was used in 105 of these 222 patients. Among them, 31 cases were of obese patients, and 26 cases were of high-volume renal cancer patients. The other 117 patients had undergone RRN without the use of ETM. Among them, 36 cases were of obese patients, and 28 cases were of high-volume renal cancer patients. The differences in age, BMI, tumor position, and tumor size between the two groups were not statistically significant, P > 0.05. Both the surgical time and the blood loss for the ETM group were significantly lower than the control group, p < 0.05. In the subgroup analysis, the obese patients and patients with high tumor volume also showed a significantly lower surgical time and less blood loss, p < 0.05. The postoperative hospitalization time, the total survival rate, and the disease-free survival rate were not statistically significant, p > 0.05. CONCLUSIONS: The use of ETM in removing the retroperitoneal fat during the RRN can potentially reduce the surgical time and lessen the blood loss. This technique is especially advantageous for obese and large-volume tumor patients. BioMed Central 2020-04-17 /pmc/articles/PMC7164161/ /pubmed/32303216 http://dx.doi.org/10.1186/s12893-020-00740-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yang, Guang
Xu, Yong
Wan, Shaw P.
Qu, Genyi
Nie, Haibo
Duan, Guangjun
Use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy
title Use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy
title_full Use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy
title_fullStr Use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy
title_full_unstemmed Use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy
title_short Use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy
title_sort use of endoscopic tissue morcellator in removing retroperitoneal fat in retroperitoneoscopic radical nephrectomy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164161/
https://www.ncbi.nlm.nih.gov/pubmed/32303216
http://dx.doi.org/10.1186/s12893-020-00740-9
work_keys_str_mv AT yangguang useofendoscopictissuemorcellatorinremovingretroperitonealfatinretroperitoneoscopicradicalnephrectomy
AT xuyong useofendoscopictissuemorcellatorinremovingretroperitonealfatinretroperitoneoscopicradicalnephrectomy
AT wanshawp useofendoscopictissuemorcellatorinremovingretroperitonealfatinretroperitoneoscopicradicalnephrectomy
AT qugenyi useofendoscopictissuemorcellatorinremovingretroperitonealfatinretroperitoneoscopicradicalnephrectomy
AT niehaibo useofendoscopictissuemorcellatorinremovingretroperitonealfatinretroperitoneoscopicradicalnephrectomy
AT duanguangjun useofendoscopictissuemorcellatorinremovingretroperitonealfatinretroperitoneoscopicradicalnephrectomy